Risk of a major adverse cardiovascular event emerged at 20 per cent total plaque burden among women and 28 per cent for men.

The risk for major adverse cardiovascular events is a recognized, important complication reported among patients with ANCA-associated vasculitis.

Please provide your email address to receive an email when new articles are posted on . Evolocumab is the first PCSK9 inhibitor to demonstrate effectiveness in primary and secondary prevention ...

Investigators from Mass General Brigham analyzed data from nearly 4,300 stable outpatients with chest pain and no known prior CAD and found that, although women had smaller plaque volumes and fewer ...

BACKGROUND: Inconsistent selection of reference groups may contribute to inconclusive blood pressure control targets for patients with hypertension. This study aims to identify optimal systolic blood ...

Semaglutide reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease regardless of baseline adiposity. Cardiovascular benefit was largely ...

Find out more about how metabolic and bariatric surgery offers greater cardiovascular protection than GLP-1 receptor agonists.

Patients with gout who achieve a serum urate level lower than 6 mg/dL demonstrated a lower 5-year risk for cardiovascular ...

MALAGA, Spain—Clinicians caring for patients with obesity or overweight and established cardiovascular disease should start patients on semaglutide (Wegovy; Novo Nordisk) as soon as possible. That’s ...

Despite these limitations, the findings suggest that GLP-1 receptor agonists may provide important limb, cardiovascular, and renal protection in patients with diabetes and prior MALEs, supporting ...

Semaglutide, the active ingredient in the anti-obesity drug Wegovy, offers cardiovascular benefits for patients without diabetes who have established heart disease, but price reductions would be ...